Vera Therapeutics to Participate at September Investor Conferences
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotech company, announced its participation in two investor conferences in September 2024. The company, which focuses on developing treatments for serious immunological diseases, will attend:
1. Wells Fargo Healthcare Conference on September 5 in Boston, MA, participating in one-on-one meetings.
2. Cantor Global Healthcare Conference on September 18 in New York, NY, featuring a fireside chat at 9:10am EDT and one-on-one meetings.
A webcast of the Cantor conference presentation will be available, with a 90-day replay accessible on Vera Therapeutics' website in the 'Investor Calendar' section.
Vera Therapeutics (Nasdaq: VERA), un'azienda biotech in fase avanzata, ha annunciato la sua partecipazione a due conferenze per investitori a settembre 2024. L'azienda, che si concentra sullo sviluppo di trattamenti per gravi malattie immunologiche, parteciperà a:
1. Wells Fargo Healthcare Conference il 5 settembre a Boston, MA, partecipando a incontri individuali.
2. Cantor Global Healthcare Conference il 18 settembre a New York, NY, con una chiacchierata informale alle 9:10 EDT e incontri individuali.
Un webcast della presentazione alla conferenza Cantor sarà disponibile, con una replica accessibile per 90 giorni sul sito web di Vera Therapeutics nella sezione 'Calendario Investitori'.
Vera Therapeutics (Nasdaq: VERA), una compañía biotecnológica en etapa clínica avanzada, anunció su participación en dos conferencias para inversores en septiembre de 2024. La empresa, que se enfoca en desarrollar tratamientos para enfermedades inmunológicas graves, asistirá a:
1. Wells Fargo Healthcare Conference el 5 de septiembre en Boston, MA, participando en reuniones individuales.
2. Cantor Global Healthcare Conference el 18 de septiembre en Nueva York, NY, con una charla informal a las 9:10 a.m. EDT y reuniones individuales.
Una transmisión de la presentación en la conferencia Cantor estará disponible, con una repetición accesible durante 90 días en el sitio web de Vera Therapeutics en la sección 'Calendario de Inversores'.
베라 테라퓨틱스 (Nasdaq: VERA), 후기 임상 단계의 생명공학 회사가 2024년 9월 두 개의 투자자 회의에 참석할 것이라고 발표했다. 중대한 면역질환 치료 개발에 집중하는 이 회사는 다음과 같은 회의에 참석할 예정이다:
1. 웰스 파고 헬스케어 컨퍼런스가 9월 5일 보스턴, MA에서 열리며, 개별 미팅에 참여할 예정입니다.
2. 칸토 글로벌 헬스케어 컨퍼런스가 9월 18일 뉴욕, NY에서 열리며, 오전 9:10 EDT에 대담이 진행되고 개별 미팅이 있을 예정입니다.
칸토 회의 발표의 웹캐스트가 제공되며, 베라 테라퓨틱스의 웹사이트 '투자자 일정' 섹션에서 90일 동안 다시 볼 수 있습니다.
Vera Therapeutics (Nasdaq: VERA), une entreprise biopharmaceutique en phase clinique avancée, a annoncé sa participation à deux conférences pour investisseurs en septembre 2024. L'entreprise, qui se concentre sur le développement de traitements pour des maladies immunologiques graves, assistera à :
1. Wells Fargo Healthcare Conference le 5 septembre à Boston, MA, participant à des réunions individuelles.
2. Cantor Global Healthcare Conference le 18 septembre à New York, NY, avec une discussion informelle à 9h10 EDT et des réunions individuelles.
Un webinaire de la présentation de la conférence Cantor sera disponible, avec une rediffusion accessible pendant 90 jours sur le site web de Vera Therapeutics dans la section 'Calendrier des investisseurs'.
Vera Therapeutics (Nasdaq: VERA), ein Biotech-Unternehmen in der späten klinischen Phase, gab seine Teilnahme an zwei Investorenkonferenzen im September 2024 bekannt. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für schwere immunologische Erkrankungen konzentriert, wird an folgenden Veranstaltungen teilnehmen:
1. Wells Fargo Healthcare Conference am 5. September in Boston, MA, mit Einzelgesprächen.
2. Cantor Global Healthcare Conference am 18. September in New York, NY, mit einem informellen Gespräch um 9:10 Uhr EDT und Einzelgesprächen.
Ein Webcast der Präsentation bei der Cantor-Konferenz wird verfügbar sein, mit einer 90-tägigen Wiederholung, die auf der Website von Vera Therapeutics im Abschnitt 'Investorenkalender' zugänglich ist.
- None.
- None.
BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at investor conferences being held in September.
Investor Conference Details:
- Wells Fargo Healthcare Conference
Format: 1x1s
Date: Thursday, September 5, 2024
Location: Boston, MA - Cantor Global Healthcare Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/cantor22/vera/2084634
Date: Wednesday, September 18, 2024
Time: 9:10am EDT
Location: New York, NY
A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Advisors
MHawtin@lifescicomms.com
FAQ
What investor conferences will Vera Therapeutics (VERA) attend in September 2024?
When is Vera Therapeutics (VERA) presenting at the Cantor Global Healthcare Conference?
Where can I watch the webcast of Vera Therapeutics' (VERA) presentation at the Cantor conference?
What type of company is Vera Therapeutics (VERA)?
